'We Are Working On Several Projects That Will Result In Some Revolutionary Film Coating Products'

Suresh Pareek,MD, Ideal Cures, elaborates on his company's offerings for the pharma sector, its growth strategies and his expectations from CPhI 2016, in an interview with Viveka Roychowdhury

- Viveka Roychowdhury

What have been the dominant trends in pharma excipients and film coating systems in 2016?

Quality, service and supply excellence are pre-requisites to be a vendor to the pharma industry. The major trend has been responding to reducing supply risk. As a result, there has been an increase in qualification of alternate excipient vendors who have the right credentials such as cGMP manufacturing with ISO and EXCiPACT certification by discerning pharma manufacturers.

What have been the major drivers of these trends?

There are obvious drivers such as supply chain security to reduce dependence on monopolistic suppliers and encourage healthy competition. The not so obvious one is to limit the proliferation of 'fighter brands' by dominant players who are moving the goal post citing cost and service standard differences to retain profit margins and hoodwink the pharma industry as it is detrimental to the industry since it promotes two-tier pricing and perception of quality. By developing alternate vendors, the dominant companies will have to compete with the premium brands at the right price.

This is actually a great service to the domestic and unregulated markets which will have access to the premium brands on par with products for the regulated markets. At Ideal Cures, we believe that all the seven billion people on this planet are first class citizens and should have access to first class medicines so we promote our first class brand 'Instacoat' for all markets.

What have been the most recent additions, line extensions to Ideal Cures' range?